Timing of Determining Axillary Lymph Node Status When Neoadjuvant Chemotherapy is Used

    Authors

    E. P. Mamounas

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Curr. Oncol. Rep.

    Keywords

    Breast cancer.; Neoadjuvant chemotherapy ( NC).; Sentinel lymph node; biopsy before or after neoadjuvant; chemotherapy.; Axillary lymph node; status.; Adjuvant chemotherapy; SURGICAL ADJUVANT BREAST; COMPARING TOTAL MASTECTOMY; FINE-NEEDLE; ASPIRATION; PROJECT PROTOCOL B-27; 20-YEAR FOLLOW-UP; SENTINEL-NODE; PREOPERATIVE CHEMOTHERAPY; CANCER PATIENTS; RADICAL-MASTECTOMY; RANDOMIZED-TRIALS; Oncology

    Abstract

    Neoadjuvant chemotherapy is the standard of care for patients with locally advanced breast cancer and is a reasonable alternative to adjuvant chemotherapy for those with large operable disease. Potential clinical advantages of neoadjuvant chemotherapy include the conversion of some patients requiring mastectomy to candidates for breast-conserving surgery, the potential for downstaging axillary nodes and thus reducing the extent of axillary surgery, and the ability to correlate clinical and pathologic response to neoadjuvant chemotherapy with improved long- term outcomes. An important and controversial locoregional therapy issue in patients who are candidates for neoadjuvant chemotherapy relates to the timing of sentinel lymph node biopsy i. e., either before or after neoadjuvant chemotherapy. This review will focus on the performance characteristics of sentinel lymph node biopsy before vs. after neoadjuvant chemotherapy and on the pros and cons of each approach.

    Journal Title

    Current Oncology Reports

    Volume

    16

    Issue/Number

    2

    Publication Date

    1-1-2014

    Document Type

    Article

    Language

    English

    First Page

    7

    WOS Identifier

    WOS:000334168700001

    ISSN

    1523-3790

    Share

    COinS